LIGHT deficiency aggravates cisplatin-induced acute kidney injury by upregulating mitochondrial apoptosis

•Expression of LIGHT and its receptors HVEM and LTβR was increased in kidney tissues of mice after cisplatin treatment.•LIGHT deficiency aggravated cisplatin-induced kidney injury in mice.•Absence of LIGHT caused more cisplatin-induced mitochondrion apoptosis.•rLIGHT treatment alleviated cisplatin-i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International immunopharmacology 2020-12, Vol.89, p.106999, Article 106999
Hauptverfasser: Yang, Yan, Meng, Li, Wu, Shun, Li, You, Zhong, Yu, Xu, Feng, Zhou, Xiao-cui, Li, Gui-qing, Xu, Gui-lian, Peng, Kan-fu
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Expression of LIGHT and its receptors HVEM and LTβR was increased in kidney tissues of mice after cisplatin treatment.•LIGHT deficiency aggravated cisplatin-induced kidney injury in mice.•Absence of LIGHT caused more cisplatin-induced mitochondrion apoptosis.•rLIGHT treatment alleviated cisplatin-induced mitochondrion dysfunction and reduced cells apoptosis in HK-2. Cisplatin is widely used as a chemotherapeutic agent for treating patients with solid tumors. The most common side effect of cisplatin treatment is nephrotoxicity. Recent studies have shown that mitochondrial apoptotic pathways are involved in cisplatin-induced acute kidney injury (Cis-AKI). LIGHT, the 14th member of the tumor necrosis factor superfamily (TNFSF14), was found to induce apoptosis of certain types of tumor cells. So far, a link between LIGHT and Cis-AKI has not been reported. In this study, we observed that expression of LIGHT and its receptors HVEM and LTβR was increased in kidney tissues of mice after cisplatin treatment. LIGHT deficiency aggravated kidney injury, as evidenced by more severe tubular injury; remarkably increased levels of serum creatinine (Scr), blood urea nitrogen (BUN), and both kidney injury molecule-1 (KIM-1) and inflammatory cytokine mRNAs in renal tissues. Moreover, in the renal tissues of LIGHT KO mice, cisplatin-induced mitochondrion injury and the levels of the pro-apoptotic molecules Bax, Cytochrome C (Cyt C), cleaved caspase-3, and cleaved caspase-9 were dramatically increased; in contrast, the expression of anti-apoptotic molecule Bcl-2 was markedly reduced, compared to those in WT mice, suggesting that LIGHT deficiency accelerated cisplatin-induced mitochondrial apoptosis of renal tubular cells in these mice. Accordingly, treatment with recombinant human LIGHT (rLIGHT) was shown to alleviate cisplatin-induced kidney injury in vivo. Similar results were observed after the human renal tubular epithelial cell line HK-2 cells exposure to rLIGHT stimulation, evidenced by the reduction in the mitochondrion dysfunction (as confirmed by the significant reduced oxidative stress and membrane potential changes) and in the percentage of cells apoptosis. While blocking LIGHT with the soluble fusion protein LTβR-Ig or HVEM-Ig accelerated the HK-2 cells apoptosis. In conclusion, LIGHT deficiency aggravates Cis-AKI by promoting mitochondrial apoptosis pathways.
ISSN:1567-5769
1878-1705
DOI:10.1016/j.intimp.2020.106999